Talis Biomedical Corp. (TLIS): רווח נקי למניה (EPS TTM)
Talis Biomedical is seeking patent monetization pathways and strategic deals to rescue the business. On GURU.Markets, the TTM annual earnings per share visualizes the market reaction, with the metric holding at -27.91. Revenues are based on the sale of rapid diagnostic systems and consumable cartridges, however, a slow sales rollout has led to excessive costs and negative operating leverage.
פילוחים אנליטיים ודוחות נתונים של חברת Talis Biomedical Corp. (TLIS)
Investing in Talis Biomedical (TLIS) requires a rigorous fundamental analysis of its current financial standing. This indicator measures the business's actual annual earnings per share, excluding distortions from share buybacks. By analyzing the rolling annual earnings per share of Talis Biomedical (TLIS) on GURU.Markets, an investor can discern the actual efficiency of capital. This metric is critical for Talis Biomedical (TLIS) amid a total halt in R&D and commercial stagnation. The negative trend here confirms a lack of operating profit.
